reports
Achieve Life Sciences Reports Second Quarter 2025 Financial Results; P...
Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program Conference Call Scheduled for 8:30 AM EDT Today, August 7, 2025 SEATTLE and VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for second quarter 2025. “This quarter represents a significant step forward f...
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Morning Bulletin - 5 August 2025
Slight decrease of SOFIX (1 039.68, -0.07%) reflected the drop of Telematic Interactive (TIB, BGN 22.20, -2.63%), Chimimport (CHIM, BGN 0.725, -2.03%) and Sirma Group Holding (SGH, BGN 1.42, -1.39%) on Monday. Support for the main index came from Wiser (WISR, BGN 5.65, +1.80%) and Bulgarian Real Estate Fund (BREF, BGN 5.15, +0.98%). Sopharma (SFA, BGN 2.44, -0.41%) registered BGN 1.92m daily turnover as a block trade with 770k shares was registered at BGN 2.43.
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Weekly bulletin - 28 July - 1 August 2025
Moderate performance in Q2 reports published last week waned investors sentiment. Local indexes remained unchanged despite the increased weekly turnover (BGN 52.5m) mainly registered by block trades. Huge opposite moves of SOFIX members fixed the main index at 1040.37 (-0.1) as Shelly Group (SLYG, EUR 48.60, -1.8%), Bulgarian Real Estate Fund (BREF, BGN 5.10, -1.9%) and CB Central Cooperative Bank (CCB, BGN 1.71, -1.7%) wiped out the positive moves of Wiser Technology (WISR, BGN 5.55, +2.8%), Ch...
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Morning Bulletin - 31 July 2025
Selling pressure in key constituents Chimimport (CHIM, BGN 0.715, -2.05%) and Sopharma (SFA, BGN 2.44, -0.41%) nudged the SOFIX slightly lower by 0.03% to 1 042.97 on Wednesday. In contrast, the broader indexes outperformed, supported by gains in M+S Hydraulic (MSH, BGN 10.20, +2.51%) and Stara Planina Hold (SPH, BGN 9.30, +5.08%). The BGBX40 rose 0.21% to 192.00, while the BGTR30 added 0.19% to 951.29. Turnover remained well above average, driven in part by activity in less frequently traded st...
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology...
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference SEATTLE and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will participate in the BTIG Virtual Biotechnology Conference being held July 29-30, 2025. Rick Stewart, Chief Executive Officer of Achieve, will participate in a fireside chat wit...
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Morning Bulletin - 28 July 2025
Huge selling pressure on Shelly (SLYG, EUR 49.50) and Bulgarian Real Estate Fund (BREF, BGN 5.20) settled both companies unchanged on Friday. SOFIX 1041.64 (-0.17%) slightly retreated on the ground of moderate daily turnover. Sopharma (SFA, BGN 2.43, -1.22%) ceased its positive wave during the week after the release of the new dividend shares for trading. Sirma Group (SGH, BGN 1.43, -0.69%) and Bulgarian Stock Exchange (BSE, BGN 9.00, -0.55%) also weighed on the main index by losing altitude wit...
Achieve Life Sciences to Announce Second Quarter Financial Results and...
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025 SEATTLE and VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its second quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, August 7, 2025, ...
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Morning Bulletin - 22 July 2025
A mixed trading session fixed SOFIX (1 045.48, +0.18%) positive. The north moves of Shelly (SLYG, EUR 49.90, +2.46%), Bulgarian Real Estate Fund (BREF, BGN 5.20, +0.97%) and Telematic Interactive (TIB, BGN 22.60, +0.89%) offset the negative impact of Wiser (WISR, BGN 5.15, -2.83%), First Investment Bank (FIB, BGN 5.06, -1.17%) and Chimimport (CHIM, BGN 0.74, -1.33%). Advance Terrafund (ATER, BGN 2.98, -0.67%) stepped back but BGREIT (231.19, +0.06%) closed in the green zone. Overall liquidity re...
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Weekly bulletin - 13 July - 18 July 2025
The past week was negative for the major indexes on the Bulgarian Stock Exchange, with SOFIX (1 043.55) recording the largest decline, down 1.0%. Key underperformers from our watchlist that dragged the indexes lower included Neochim (NEOH, BGN 20.00, -7.4%), Stara Planina Hold (SPH, BGN 9.00, -7.2%), and Sopharma (SFA, BGN 2.49, -4.2%). In contrast, BGREIT (231.04) edged up by 0.05%, supported by gains in its heaviest constituents – Advance Terrafund (ATER, BGN 3.00, +0.7%) and Bulgarian Real Es...
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Morning Bulletin - 17 July 2025
Wednesday’s session was subdued, with decliners outpacing advancers by a roughly 2-to-1 margin, pushing the major indexes into negative territory. SOFIX declined by 0.17% to 1 051.45, weighed down by losses in Smart Organic (SO, BGN 31.80, -1.24%) and Advance Terrafund (ATER, BGN 2.96, -1.33%). On a positive note, Bulgarian Real Estate Fund (BREF, BGN 5.10, +2.41%) was among the top gainers, helping the BGREIT index to edge up by 0.21% to 229.95. Overall trading activity weakened, with volumes s...
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Weekly bulletin - 30 June - 4 July 2025
The Bulgarian stock market edged slightly lower last week, as investor activity did not improve and there was no clear point for the market during ongoing summer season. The benchmark SOFIX retreated 0.2% to settle at 1023.43, as the broad ones- BGBX40 (188.48, -0.2%) and BGTR30 (938.83, -0.3%) performed the same. The weekly volume (-68.5%) showed weak performance, while the turnover (+50.7%) was pushed up by intense trade with bonds and some particular positions. The top gainers within our list...
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Morning Bulletin - 4 July 2025
The Bulgarian equity market finished on a weak note on Thursday as trading activity remaining narrowly ranged with lower volumes. The main indexes ended in negative territory with declines ranging from -0.30% to -0.48%. BGTREIT (227.19, +0.33%) performed differently, supported by the advance of the Bulgarian Real Estate Fund (BREF, BGN 5.05, +1.41%). Wiser Technologies (WISR, BGN 5.10, -4.67%), Smart Organic (SO, BGN 32.00, -3.61%) and Agria Group (AGH, BGN 20.00, -3.85%) topped the laggards lis...
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Morning Bulletin - 2 July 2025
Yesterday was the first trading day of the third quarter, and it was dominated by a narrow range of large-cap names. The tech sector – represented by Wiser Technologies (WISR, BGN 5.15, -3.74%), Sirma Group (SGH, BGN 1.40, -2.78%), and Shelly (SLYG, EUR 47.60, -0.63%) – took a step back during the session, dragging SOFIX (1019.96) down by 0.51%. A small trade in Speedy (SPDY, BGN 202.00), amid a widened order book, registered an 8.02% gain for the courier company and helped push the broader inde...
Achieve Life Sciences Announces Closing of Public Offering of Common S...
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the closing of its underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to p...
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Weekly bulletin - 23 June - 27 June 2025
Green color and huge weekly turnover set SOFIX at 1025.22 (+1.8%) – level we haven’t seen since September 2008. Weekly turnover tripled and reached BGN 44m., compared to the average one YTD of BGN 15.6m. Main distributors for the increased volume were Doverie Unted Holding’s buy-back and Sopharma’s sales of its treasury shares. The week was highlighted also by the first IPO this year of Green Innovation which raised almost BGN 8m. on Tuesday.
- Mihail Dimitrov
- Veselin Radoychev Please Change Surname
Morning Bulletin - 27 June 2025
The real estate sector led Thursday’s gains on the local stock exchange with Advance Terrafund (ATER, BGN 2.95, +2.08%) and Bulgarian Real Estate Fund (BREF, BGN 4.94, +2.07%) acting as key drivers. Their performance supported broad-based growth across all major indexes, which closed higher in a range between 0.46% and 1.35%. SOFIX added 0.53% to reach 1 013.89 points, supported by gains in Shelly Group (SLYG, EUR 49.40, +0.61%). Meanwhile, the broader indexes also advanced: BGBX40 rose 0.46% to...
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten ...
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 15,000,000 shares of common stock. The shares of common...
Achieve Life Sciences Announces Proposed Underwritten Public Offering
Achieve Life Sciences Announces Proposed Underwritten Public Offering SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to pu...
Achieve Life Sciences Announces Partnership with Omnicom to Execute In...
Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialt...
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinic...
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades More than 2,000 clinical trial participants contributed to the body of evidence submitted in the NDA demonstrating cytisinicline’s efficacy, safety, and tolerability profile SEATTLE and VANCOUVER, British Colum...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.